無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インスリン製剤のバイオシミラー市場の世界市場:成長動向と競合分析:2018年〜2025年

Global Biosimilars Insulin Industry Research Report, Growth Trends and Competitive Analysis 2018-2025

発行 QYResearch 商品コード 691701
出版日 ページ情報 英文 110 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=113.36円で換算しております。
Back to Top
インスリン製剤のバイオシミラー市場の世界市場:成長動向と競合分析:2018年〜2025年 Global Biosimilars Insulin Industry Research Report, Growth Trends and Competitive Analysis 2018-2025
出版日: 2018年09月04日 ページ情報: 英文 110 Pages
概要

当レポートでは、世界のインスリン製剤のバイオシミラー市場を調査し、市場の概要、タイプ・用途・地域別の市場動向、売上数・収益額の推移と予測(過去5年、今後8年間分)、市場シェア、市場の成長要因、主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 市場概要

  • 調査範囲
  • 調査対象の製薬企業
  • 市場区分:タイプ別
    • バサグラー(インスリングラルギン)
    • ランタス(インスリン)
  • 市場区分:用途別
    • 1型糖尿病
    • 2型糖尿病
  • 調査目的
  • 調査期間

第2章 成長動向

  • 市場規模
    • 収益額
    • 売上数
  • 地域別の成長率
  • 産業動向
    • 主な市場動向
    • 市場促進要因

第3章 市場シェア:企業別

  • インスリン製剤のバイオシミラーの売上数:企業別
    • 売上数の推移
    • 売上シェア
  • インスリン製剤のバイオシミラーの収益額:企業別
    • 収益額の推移
    • 収益シェア
    • 企業の市場集中度
  • 医薬品価格:企業別
  • 主要企業の生産拠点・工場の分布
  • 主要企業の市場参入時期
  • 主要企業の製品
  • 合併・買収・事業拡大計画

第4章 市場規模:タイプ別

  • 売上数と収益額の推移:タイプ別
  • 売上シェア:タイプ別
  • 収益シェア:タイプ別
  • 価格:タイプ別

第5章 市場規模:用途別

  • 市場概要
  • 売上数:用途別

第6章 北米のインスリン製剤のバイオシミラー市場

  • 市場内訳:企業別
  • 市場内訳:タイプ別
  • 市場内訳:用途別
  • 市場内訳:国別
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のインスリン製剤のバイオシミラー市場

  • 市場内訳:企業別
  • 市場内訳:タイプ別
  • 市場内訳:用途別
  • 市場内訳:国別
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 アジア太平洋のインスリン製剤のバイオシミラー市場

  • 市場内訳:企業別
  • 市場内訳:タイプ別
  • 市場内訳:用途別
  • 市場内訳:国別
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • インドネシア
    • マレーシア
    • フィリピン
    • タイ
    • ベトナム

第9章 中南米のインスリン製剤のバイオシミラー市場

  • 市場内訳:企業別
  • 市場内訳:タイプ別
  • 市場内訳:用途別
  • 市場内訳:国別
    • ブラジル

第10章 中東・アフリカのインスリン製剤のバイオシミラー市場

  • 市場内訳:企業別
  • 市場内訳:タイプ別
  • 市場内訳:用途別
  • 市場内訳:地域/国別
    • 湾岸協力会議(GCC)
    • エジプト
    • 南アフリカ

第11章 企業プロファイル

  • Eli Lilly
  • Boehringer Ingelheim
  • Merck
  • Pfizer
  • Biocon
  • Mylan

第12章 バリューチェーンと販売チャネルの分析

  • バリューチェーン分析
  • 販売チャネル分析
    • 販売チャネル
    • 流通業者
  • 顧客

第13章 市場予測

  • 売上数と収益額の予測
  • 売上数の予測:タイプ別
  • 売上数の予測:用途別
  • 市場予測:地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 中南米
  • 中東・アフリカ

第14 調査結果と総論

第15章 付録

図表

List of Tables and Figures

  • Figure Biosimilars Insulin Product Picture
  • Table Biosimilars Insulin Key Market Segments
  • Table Major Manufacturers Biosimilars Insulin Covered in This Report
  • Table Global Biosimilars Insulin Market Size Growth Rate by Type 2018-2025 (K MT) & (Million US$)
  • Figure Global Biosimilars Insulin Sales Market Shar by Type 2013-2025
  • Figure Insulin Glargine Basaglar Figures
  • Figure Biosimilars Insulin Report Years Considered
  • Figure Global Biosimilars Insulin Market Size 2013-2025 (Million US$)
  • Figure Global Biosimilars Insulin Sales 2013-2018 (K MT)
  • Table Global Biosimilars Insulin Market Size by Regions 2013-2018 (K MT) & (Million US$)
  • Table Global Biosimilars Insulin Sales by Regions 2013-2018 (K MT)
  • Table Global Biosimilars Insulin Sales Market Share by Regions 2013-2018
  • Figure Global Biosimilars Insulin Sales Market Share by Regions 2013-2018
  • Figure Global Biosimilars Insulin Sales Market Share by Regions in 2018
  • Table Global Biosimilars Insulin Revenue by Regions 2013-2018 (Million US$)
  • Table Global Biosimilars Insulin Revenue Market Share by Regions 2013-2018
  • Figure Global Biosimilars Insulin Revenue Market Share by Regions 2013-2018
  • Figure Global Biosimilars Insulin Revenue Market Share by Regions in 2018
  • Table Market Top Trends
  • Table Global Biosimilars Insulin Sales by Manufacturers (2013-2018) (K MT)
  • Table Global Biosimilars Insulin Sales Share by Manufacturers (2013-2018)
  • Figure Global Biosimilars Insulin Sales Share by Manufacturers in 2018
  • Table Biosimilars Insulin Revenue by Manufacturers (2013-2018) (Million USD)
  • Table Biosimilars Insulin Revenue Share by Manufacturers (2013-2018)
  • Figure Biosimilars Insulin Value Share by Manufacturers in 2018
  • Table Global Biosimilars Insulin Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table Key Manufacturers Biosimilars Insulin Price (2013-2018) (USD/MT)
  • Table Key Manufacturers Biosimilars Insulin Plants/Factories Distribution
  • Table Key Manufacturers Biosimilars Insulin Area Served
  • Table Date of Key Manufacturers Enter into Biosimilars Insulin Market
  • Table Key Manufacturers Biosimilars Insulin Product Type
  • Table Global Biosimilars Insulin Sales by Type (2013-2018) (K MT)
  • Table Global Biosimilars Insulin Sales Share by Type (2013-2018)
  • Figure Global Biosimilars Insulin Sales Market Share by Type (2013-2018)
  • Figure Global Biosimilars Insulin Sales Market Share by Type in 2017
  • Table Global Biosimilars Insulin Revenue by Type (2013-2018) (Million US$)
  • Table Global Biosimilars Insulin Revenue Share by Type (2013-2018)
  • Figure Global Biosimilars Insulin Revenue Market Share by Type (2013-2018)
  • Figure Global Biosimilars Insulin Revenue Market Share by Type in 2017
  • Table Biosimilars Insulin Price by Type 2013-2018 (USD/MT)
  • Table Global Biosimilars Insulin Sales by Application (2013-2018) (K MT)
  • Table Global Biosimilars Insulin Sales Share by Application (2013-2018)
  • Figure Global Sales Biosimilars Insulin Market Share by Application (2013-2018)
  • Figure Global Sales Biosimilars Insulin Market Share by Application in 2017
  • Figure North America Biosimilars Insulin Sales Growth Rate 2013-2018 (K MT)
  • Figure North America Biosimilars Insulin Revenue Growth Rate 2013-2018 (Million US$)
  • Table North America Biosimilars Insulin Sales by Company (2013-2018) (K MT)
  • Table North America Biosimilars Insulin Sales Market Share by Company (2013-2018)
  • Figure North America Biosimilars Insulin Sales Market Share by Company in 2018
  • Table North America Biosimilars Insulin Sales by Type (2013-2018) (K MT)
  • Table North America Biosimilars Insulin Sales Market Share by Type (2013-2018)
  • Figure North America Biosimilars Insulin Market Share by Type in 2018
  • Table North America Biosimilars Insulin Sales by Application (2013-2018) (K MT)
  • Table North America Biosimilars Insulin Sales Market Share by Application (2013-2018)
  • Figure North America Biosimilars Insulin Market Share by Application in 2018
  • Table North America Biosimilars Insulin Sales by Countries (2013-2018) (K MT)
  • Table North America Biosimilars Insulin Sales Market Share by Countries (2013-2018)
  • Figure 2017 North America Biosimilars Insulin Sales Market Share by Countries
  • Table North America Biosimilars Insulin Revenue by Countries (2013-2018) (Million US$)
  • Table North America Biosimilars Insulin Revenue Market Share by Countries (2013-2018)
  • Figure 2017 North America Biosimilars Insulin Revenue Market Share by Countries
  • Figure United States Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Canada Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Mexico Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Europe Biosimilars Insulin Sales Growth Rate 2013-2018 (K MT)
  • Figure Europe Biosimilars Insulin Revenue Growth Rate 2013-2018 (Million US$)
  • Table Europe Biosimilars Insulin Sales by Company (2013-2018) (K MT)
  • Table Europe Biosimilars Insulin Sales Market Share by Company (2013-2018)
  • Figure Europe Biosimilars Insulin Sales Market Share by Company in 2018
  • Table Europe Biosimilars Insulin Sales by Type (2013-2018) (K MT)
  • Table Europe Biosimilars Insulin Sales Market Share by Type (2013-2018)
  • Figure 2017 Europe Biosimilars Insulin Market Share by Type
  • Table Europe Biosimilars Insulin Sales by Application (2013-2018) (K MT)
  • Table Europe Biosimilars Insulin Sales Market Share by Application (2013-2018)
  • Figure 2017 Europe Biosimilars Insulin Market Share by Application
  • Table Europe Biosimilars Insulin Sales by Countries (2013-2018) (K MT)
  • Table Europe Biosimilars Insulin Sales Market Share by Countries (2013-2018)
  • Figure 2017 Europe Biosimilars Insulin Sales Market Share by Countries
  • Table Europe Biosimilars Insulin Revenue by Countries (2013-2018) (Million US$)
  • Table Europe Biosimilars Insulin Revenue Market Share by Countries (2013-2018)
  • Figure Europe Biosimilars Insulin Revenue Market Share by Countries in 2018
  • Figure Germany Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure France Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure UK Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Italy Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Russia Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Asia Pacific Biosimilars Insulin Sales Growth Rate 2013-2018 (K MT)
  • Figure Asia Pacific Biosimilars Insulin Revenue Growth Rate 2013-2018 (Million US$)
  • Table Asia Pacific Biosimilars Insulin Sales by Company (2013-2018) (K MT)
  • Table Asia Pacific Biosimilars Insulin Sales Market Share by Company (2013-2018)
  • Figure Asia Pacific Biosimilars Insulin Sales Market Share by Company in 2018
  • Table Asia Pacific Biosimilars Insulin Sales by Type (2013-2018) (K MT)
  • Table Asia Pacific Biosimilars Insulin Sales Market Share by Type (2013-2018)
  • Figure Asia Pacific Biosimilars Insulin Market Share by Type in 2018
  • Table Asia Pacific Biosimilars Insulin Sales by Application (2013-2018) (K MT)
  • Table Asia Pacific Biosimilars Insulin Sales Market Share by Application (2013-2018)
  • Figure Asia Pacific Biosimilars Insulin Market Share by Application in 2018
  • Table Asia Pacific Biosimilars Insulin Sales by Countries (2013-2018) (K MT)
  • Table Asia Pacific Biosimilars Insulin Sales Market Share by Countries (2013-2018)
  • Figure 2017 Asia Pacific Biosimilars Insulin Sales Market Share by Countries
  • Table Asia Pacific Biosimilars Insulin Revenue by Countries (2013-2018) (Million US$)
  • Table Asia Pacific Biosimilars Insulin Revenue Market Share by Countries (2013-2018)
  • Figure 2017 Asia Pacific Biosimilars Insulin Revenue Market Share by Countries
  • Figure China Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure China Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Japan Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Japan Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Korea Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Korea Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure India Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure India Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Australia Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Australia Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Indonesia Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Indonesia Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Malaysia Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Malaysia Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Philippines Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Philippines Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Thailand Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Thailand Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Vietnam Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Vietnam Biosimilars Insulin Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Central & South America Biosimilars Insulin Sales Growth Rate 2013-2018 (K MT)
  • Figure Central & South America Biosimilars Insulin Revenue Growth Rate 2013-2018 (Million US$)
  • Table Central & South America Biosimilars Insulin Sales by Company (2013-2018) (K MT)
  • Table Central & South America Biosimilars Insulin Sales Market Share by Company (2013-2018)
  • Figure Central & South America Biosimilars Insulin Sales Market Share by Company in 2018
  • Table Central & South America Biosimilars Insulin Sales by Type (2013-2018) (K MT)
  • Table Central & South America Biosimilars Insulin Sales Market Share by Type (2013-2018)
  • Figure Central & South America Biosimilars Insulin Market Share by Type in 2018
  • Table Central & South America Biosimilars Insulin Sales by Application (2013-2018) (K MT)
  • Table Central & South America Biosimilars Insulin Sales Market Share by Application (2013-2018)
  • Figure Central & South America Biosimilars Insulin Market Share by Application in 2018
  • Table Central & South America Biosimilars Insulin Sales by Countries (2013-2018) (K MT)
  • Table Central & South America Biosimilars Insulin Sales Market Share by Countries (2013-2018)
  • Figure Central & South America Biosimilars Insulin Sales Market Share by Countries in 2018
  • Table Central & South America Biosimilars Insulin Revenue by Countries (2013-2018) (Million US$)
  • Table Central & South America Biosimilars Insulin Revenue Market Share by Countries (2013-2018)
  • Figure Central & South America Biosimilars Insulin Revenue Market Share by Countries in 2018
  • Figure Brazil Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Brazil Biosimilars Insulin Revenue Growth Rate (2013-2018) (K MT)
  • Figure Middle East and Africa Biosimilars Insulin Sales Growth Rate 2013-2018 (K MT)
  • Figure Middle East and Africa Biosimilars Insulin Revenue Growth Rate 2013-2018 (Million US$)
  • Table Middle East and Africa Biosimilars Insulin Sales by Type (2013-2018) (K MT)
  • Table Middle East and Africa Biosimilars Insulin Sales Market Share by Type (2013-2018)
  • Figure 2017 Middle East and Africa Biosimilars Insulin Market Share by Type
  • Table Middle East and Africa Biosimilars Insulin Sales by Application (2013-2018) (K MT)
  • Table Middle East and Africa Biosimilars Insulin Sales Market Share by Application (2013-2018)
  • Figure 2017 Middle East and Africa Biosimilars Insulin Market Share by Application
  • Table Middle East and Africa Biosimilars Insulin Sales by Countries (2013-2018) (K MT)
  • Table Middle East and Africa Biosimilars Insulin Sales Market Share by Countries (2013-2018)
  • Figure 2017 Middle East and Africa Biosimilars Insulin Sales Market Share by Countries
  • Table Middle East and Africa Biosimilars Insulin Revenue by Countries (2013-2018) (Million US$)
  • Table Middle East and Africa Biosimilars Insulin Revenue Market Share by Countries (2013-2018)
  • Figure 2017 Middle East and Africa Biosimilars Insulin Revenue Market Share by Countries
  • Figure GCC Countries Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure GCC Countries Biosimilars Insulin Revenue Growth Rate (2013-2018) (K MT)
  • Figure Egypt Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure Egypt Biosimilars Insulin Revenue Growth Rate (2013-2018) (K MT)
  • Figure South Africa Biosimilars Insulin Sales Growth Rate (2013-2018) (K MT)
  • Figure South Africa Biosimilars Insulin Revenue Growth Rate (2013-2018) (K MT)
  • Table Eli Lilly Company Details
  • Table Eli Lilly Description and Business Overview
  • Table Eli Lilly Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2013-2018)
  • Table Eli Lilly Biosimilars Insulin Sales Growth Rate (2013-2018)
  • Table Eli Lilly Biosimilars Insulin Sales Market Share in Global Market
  • Table Eli Lilly Recent Development
  • Table Boehringer Ingelheim Company Details
  • Table Boehringer Ingelheim Description and Business Overview
  • Table Boehringer Ingelheim Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2013-2018)
  • Table Boehringer Ingelheim Biosimilars Insulin Sales Growth Rate (2013-2018)
  • Table Boehringer Ingelheim Biosimilars Insulin Sales Market Share in Global Market
  • Table Boehringer Ingelheim Recent Development
  • Table Merck Company Details
  • Table Merck Description and Business Overview
  • Table Merck Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2013-2018)
  • Table Merck Biosimilars Insulin Sales Growth Rate (2013-2018)
  • Table Merck Biosimilars Insulin Sales Market Share in Global Market
  • Table Merck Recent Development
  • Table Pfizer Company Details
  • Table Pfizer Description and Business Overview
  • Table Pfizer Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2013-2018)
  • Table Pfizer Biosimilars Insulin Sales Growth Rate (2013-2018)
  • Table Pfizer Biosimilars Insulin Sales Market Share in Global Market
  • Table Pfizer Recent Development
  • Table Biocon Company Details
  • Table Biocon Description and Business Overview
  • Table Biocon Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2013-2018)
  • Table Biocon Biosimilars Insulin Sales Growth Rate (2013-2018)
  • Table Biocon Biosimilars Insulin Sales Market Share in Global Market
  • Table Biocon Recent Development
  • Table Mylan Company Details
  • Table Mylan Description and Business Overview
  • Table Mylan Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2013-2018)
  • Figure Biosimilars Insulin Value Chain
  • Table Biosimilars Insulin Distributors List
  • Table Biosimilars Insulin Customers List
  • Table Global Biosimilars Insulin Sales Forecast 2018-2025 (K MT) & (Million US$)
  • Figure Global Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Global Biosimilars Insulin Revenue Forecast 2018-2025 (Million US$)
  • Table Global Biosimilars Insulin Sales Forecast by Type 2018-2025 (K MT)
  • Figure Global Biosimilars Insulin Sales Forecast by Type 2018-2025 (K MT)
  • Figure Global Biosimilars Insulin Sales Market Share Forecast by Type 2018-2025
  • Table Global Biosimilars Insulin Sales Forecast by Application 2018-2025 (K MT)
  • Figure Global Biosimilars Insulin Sales Forecast by Application 2018-2025 (K MT)
  • Figure Global Biosimilars Insulin Sales Market Share Forecast by Application 2018-2025
  • Table Global Biosimilars Insulin Sales Forecast by Regions 2018-2025 (K MT)
  • Figure Global Biosimilars Insulin Sales Forecast by Regions 2018-2025 (K MT)
  • Figure Global Biosimilars Insulin Sales Market Share Forecast by Regions 2018-2025
  • Table Global Biosimilars Insulin Revenue Forecast by Regions 2018-2025 (Million US$)
  • Figure Global Biosimilars Insulin Revenue Forecast by Regions 2018-2025 (Million US$)
  • Figure Global Biosimilars Insulin Revenue Market Share Forecast by Regions 2018-2025
  • Table North America Biosimilars Insulin Sales Forecast by Countries 2018-2025 (K MT)
  • Table North America Biosimilars Insulin Sales Market Share Forecast by Countries 2018-2025
  • Table North America Biosimilars Insulin Revenue Forecast by Countries 2018-2025 (Million US$)
  • Table North America Biosimilars Insulin Revenue Market Share Forecast by Countries 2018-2025
  • Figure United States Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Canada Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure MexicoBiosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Table Europe Biosimilars Insulin Sales Forecast by Countries 2018-2025 (K MT)
  • Table Europe Biosimilars Insulin Sales Market Share Forecast by Countries 2018-2025
  • Table Europe Biosimilars Insulin Revenue Forecast by Countries 2018-2025 (Million US$)
  • Table Europe Biosimilars Insulin Revenue Market Share Forecast by Countries 2018-2025
  • Figure Germany Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure France Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure UK Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Italy Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Russia Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Table Asia Pacific Biosimilars Insulin Sales Forecast by Countries 2018-2025 (K MT)
  • Table Asia Pacific Biosimilars Insulin Sales Market Share Forecast by Countries 2018-2025
  • Table Asia Pacific Biosimilars Insulin Revenue Forecast by Countries 2018-2025 (Million US$)
  • Table Asia Pacific Biosimilars Insulin Revenue Market Share Forecast by Countries 2018-2025
  • Figure China Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Japan Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Korea Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure India Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Australia Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Indonesia Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Thailand Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Malaysia Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Philippines Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Figure Vietnam Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Table Central & South America Biosimilars Insulin Sales Forecast by Countries 2018-2025 (K MT)
  • Table Central & South America Biosimilars Insulin Sales Market Share Forecast by Countries 2018-2025
  • Table Central & South America Biosimilars Insulin Revenue Forecast by Countries 2018-2025 (Million US$)
  • Table Central & South America Biosimilars Insulin Revenue Market Share Forecast by Countries 2018-2025
  • Figure Brazil Biosimilars Insulin Sales Forecast 2018-2025 (K MT)
  • Table Middle East and Africa Biosimilars Insulin Sales Forecast by Regions 2018-2025 (K MT)
  • Table Middle East and Africa Biosimilars Insulin Sales Market Share Forecast by Regions 2018-2025
  • Table Middle East and Africa Biosimilars Insulin Revenue Forecast by Regions 2018-2025 (Million US$)
  • Table Middle East and Africa Biosimilars Insulin Revenue Market Share Forecast by Regions 2018-2025
  • Figure GCC Countries Biosimilars Insulin Sales Growth Rate (2016-2025) (K MT)
  • Figure Egypt Biosimilars Insulin Sales Growth Rate (2016-2025) (K MT)
  • Figure South Africa Biosimilars Insulin Sales Growth Rate (2016-2025) (K MT)
  • Table Research Programs/Design for This Report
  • Figure Bottom-up and Top-down Approaches for This Report
目次

This study researches the market size of Biosimilars Insulin, presents the global Biosimilars Insulin sales and revenue by companies, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.

This report focuses on the key data information of Biosimilars Insulin in key regions like North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa, presents sales, revenue, market share, growth rate of Biosimilars Insulin for each region and countries in each region.

For top companies, this report investigates and analyzes the sales, revenue, market share and growth rate for the top players, key data from 2013 to 2018.

This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called "Insulin glargine" and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first "biosimilar" insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.

Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi's basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.

In 2018, the global Biosimilars Insulin market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Biosimilars Insulin.

This report includes the following manufacturers; we can also add the other companies as you want.

  • Eli Lilly
  • Boehringer Ingelheim
  • Merck
  • Pfizer
  • Biocon
  • Mylan
  • ...

Market Segment by Product Type

  • Insulin Glargine Basaglar
  • Insulin Lantus

Market Segment by Application

  • Type I Diabetes
  • Type II Diabetes

Market size split by Region

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Philippines
    • Thailand
    • Vietnam
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Central & South America
    • Brazil
    • Rest of Central & South America
  • Middle East & Africa
    • GCC Countries
    • Egypt
    • South Africa

The study objectives are:

  • To analyze and research the global Biosimilars Insulin status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
  • To present the key Biosimilars Insulin manufacturers, capacity, production, revenue, market share, and recent development for key players.
  • To split the breakdown data by regions, type, companies and applications.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends, drivers, influence factors in global and regions.
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Biosimilars Insulin are as follows:

  • History Year: 2013-2018
  • Base Year: 2017
  • Estimated Year: 2018
  • Forecast Year 2018 to 2025

Table of Contents

1 Report Overview

  • 1.1 Research Scope
  • 1.2 Major Manufacturers Covered in This Report
  • 1.3 Market Segment by Type
  • 1.4 Market Segment by Application
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Biosimilars Insulin Market Size
    • 2.1.1 Global Biosimilars Insulin Revenue 2013-2025
    • 2.1.2 Global Biosimilars Insulin Sales 2013-2025
  • 2.2 Biosimilars Insulin Growth Rate by Regions
    • 2.2.1 Global Biosimilars Insulin Sales by Regions 2013-2018
    • 2.2.2 Global Biosimilars Insulin Revenue by Regions 2013-2018
  • 2.3 Industry Trends
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers

3 Market Share by Manufacturers

  • 3.1 Biosimilars Insulin Sales by Manufacturers
    • 3.1.1 Biosimilars Insulin Sales by Manufacturers 2013-2018
    • 3.1.2 Biosimilars Insulin Sales Market Share by Manufacturers 2013-2018
  • 3.2 Revenue by Manufacturers
    • 3.2.1 Biosimilars Insulin Revenue by Manufacturers (2013-2018)
    • 3.2.2 Biosimilars Insulin Revenue Share by Manufacturers (2013-2018)
    • 3.2.3 Global Biosimilars Insulin Market Concentration Ratio (CR5 and HHI)
  • 3.3 Biosimilars Insulin Price by Manufacturers
  • 3.4 Key Manufacturers Biosimilars Insulin Plants/Factories Distribution and Area Served
  • 3.5 Date of Key Manufacturers Enter into Biosimilars Insulin Market
  • 3.6 Key Manufacturers Biosimilars Insulin Product Offered
  • 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.2 Global Biosimilars Insulin Sales Market Share by Type
  • 4.3 Global Biosimilars Insulin Revenue Market Share by Type
  • 4.4 Biosimilars Insulin Price by Type

5 Market Size by Application

  • 5.1 Overview
  • 5.2 Global Biosimilars Insulin Sales by Application

6 North America

  • 6.1 North America Biosimilars Insulin Breakdown Data by Company
  • 6.2 North America Biosimilars Insulin Breakdown Data by Type
  • 6.3 North America Biosimilars Insulin Breakdown Data by Application
  • 6.4 North America Biosimilars Insulin Breakdown Data by Countries
    • 6.4.1 North America Biosimilars Insulin Sales by Countries
    • 6.4.2 North America Biosimilars Insulin Revenue by Countries
    • 6.4.3 United States
    • 6.4.4 Canada
    • 6.4.5 Mexico

7 Europe

  • 7.1 Europe Biosimilars Insulin Breakdown Data by Company
  • 7.2 Europe Biosimilars Insulin Breakdown Data by Type
  • 7.3 Europe Biosimilars Insulin Breakdown Data by Application
  • 7.4 Europe Biosimilars Insulin Breakdown Data by Countries
    • 7.4.1 Europe Biosimilars Insulin Sales by Countries
    • 7.4.2 Europe Biosimilars Insulin Revenue by Countries
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 UK
    • 7.4.6 Italy
    • 7.4.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Biosimilars Insulin Breakdown Data by Company
  • 8.2 Asia Pacific Biosimilars Insulin Breakdown Data by Type
  • 8.3 Asia Pacific Biosimilars Insulin Breakdown Data by Application
  • 8.4 Asia Pacific Biosimilars Insulin Breakdown Data by Countries
    • 8.4.1 Asia Pacific Biosimilars Insulin Sales by Countries
    • 8.4.2 Asia Pacific Biosimilars Insulin Revenue by Countries
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 Korea
    • 8.4.6 India
    • 8.4.7 Australia
    • 8.4.8 Indonesia
    • 8.4.9 Malaysia
    • 8.4.10 Philippines
    • 8.4.11 Thailand
    • 8.4.12 Vietnam

9 Central & South America

  • 9.1 Central & South America Biosimilars Insulin Breakdown Data by Company
  • 9.2 Central & South America Biosimilars Insulin Breakdown Data by Type
  • 9.3 Central & South America Biosimilars Insulin Breakdown Data by Application
  • 9.4 Central & South America Biosimilars Insulin Breakdown Data by Countries
    • 9.4.1 Central & South America Biosimilars Insulin Sales by Countries
    • 9.4.2 Central & South America Biosimilars Insulin Revenue by Countries
    • 9.4.3 Brazil

10 Middle East and Africa

  • 10.1 Middle East and Africa Biosimilars Insulin Breakdown Data by Type
  • 10.2 Middle East and Africa Biosimilars Insulin Breakdown Data by Application
  • 10.3 Middle East and Africa Biosimilars Insulin Breakdown Data by Countries
    • 10.3.1 Middle East and Africa Biosimilars Insulin Sales by Countries
    • 10.3.2 Middle East and Africa Biosimilars Insulin Revenue by Countries
    • 10.3.3 GCC Countries
    • 10.3.4 Egypt
    • 10.3.5 South Africa

11 Company Profiles

  • 11.1 Eli Lilly
    • 11.1.1 Eli Lilly Company Details
    • 11.1.2 Company Description and Business Overview
    • 11.1.3 Sales, Revenue and Market Share of Biosimilars Insulin
    • 11.1.4 Biosimilars Insulin Product Introduction
    • 11.1.5 Eli Lilly Recent Development
  • 11.2 Boehringer Ingelheim
    • 11.2.1 Boehringer Ingelheim Company Details
    • 11.2.2 Company Description and Business Overview
    • 11.2.3 Sales, Revenue and Market Share of Biosimilars Insulin
    • 11.2.4 Biosimilars Insulin Product Introduction
    • 11.2.5 Boehringer Ingelheim Recent Development
  • 11.3 Merck
    • 11.3.1 Merck Company Details
    • 11.3.2 Company Description and Business Overview
    • 11.3.3 Sales, Revenue and Market Share of Biosimilars Insulin
    • 11.3.4 Biosimilars Insulin Product Introduction
    • 11.3.5 Merck Recent Development
  • 11.4 Pfizer
    • 11.4.1 Pfizer Company Details
    • 11.4.2 Company Description and Business Overview
    • 11.4.3 Sales, Revenue and Market Share of Biosimilars Insulin
    • 11.4.4 Biosimilars Insulin Product Introduction
    • 11.4.5 Pfizer Recent Development
  • 11.5 Biocon
    • 11.5.1 Biocon Company Details
    • 11.5.2 Company Description and Business Overview
    • 11.5.3 Sales, Revenue and Market Share of Biosimilars Insulin
    • 11.5.4 Biosimilars Insulin Product Introduction
    • 11.5.5 Biocon Recent Development
  • 11.6 Mylan
    • 11.6.1 Mylan Company Details
    • 11.6.2 Company Description and Business Overview

12 Value Chain and Sales Channels Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Sales Channels Analysis
    • 12.2.1 Biosimilars Insulin Sales Channels
    • 12.2.2 Biosimilars Insulin Distributors
  • 12.3 Biosimilars Insulin Customers

13 Market Forecast

  • 13.1 Global Biosimilars Insulin Sales and Revenue Forecast 2018-2025
  • 13.2 Global Biosimilars Insulin Sales Forecast by Type
  • 13.3 Global Biosimilars Insulin Sales Forecast by Application
  • 13.4 Biosimilars Insulin Forecast by Regions
    • 13.4.1 Global Biosimilars Insulin Sales Forecast by Regions 2018-2025
    • 13.4.2 Global Biosimilars Insulin Revenue Forecast by Regions 2018-2025
  • 13.5 North America Market Forecast
    • 13.5.1 North America Biosimilars Insulin Forecast by Countries 2018-2025
    • 13.5.2 United States
    • 13.5.3 Canada
    • 13.5.4 Mexico
  • 13.6 Europe Market Forecast
    • 13.6.1 Europe Biosimilars Insulin Forecast by Countries 2018-2025
    • 13.6.2 Germany
    • 13.6.3 France
    • 13.6.4 UK
    • 13.6.5 Italy
    • 13.6.6 Russia
  • 13.7 Asia Pacific Market Forecast
    • 13.7.1 Asia Pacific Biosimilars Insulin Sales Forecast by Countries 2018-2025
    • 13.7.2 China
    • 13.7.3 Japan
    • 13.7.4 Korea
    • 13.7.5 India
    • 13.7.6 Australia
    • 13.7.7 Indonesia
    • 13.7.8 Thailand
    • 13.7.9 Malaysia
    • 13.7.10 Philippines
    • 13.7.11 Vietnam
  • 13.8 Central & South America Market Forecast
    • 13.8.1 Central & South America Biosimilars Insulin Sales Forecast by Countries 2018-2025
    • 13.8.2 Brazil
  • 13.9 Middle East and Africa Market Forecast
    • 13.9.1 Middle East and Africa Biosimilars Insulin Sales Forecast by Countries 2018-2025
    • 13.9.2 GCC Countries
    • 13.9.3 Egypt
    • 13.9.4 South Africa

14 Research Findings and Conclusion

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
      • 15.1.1.1 Research Programs/Design
      • 15.1.1.2 Market Size Estimation
      • 15.1.1.3 Market Breakdown and Data Triangulation
    • 15.1.2 Data Source
      • 15.1.2.1 Secondary Sources
      • 13.1.2.2 Primary Sources
  • 15.2 Author Details
  • 15.3 Disclaimer
Back to Top